Literature DB >> 17311652

Nonalcoholic fatty liver disease in severely obese subjects.

Pierre M Gholam1, Louis Flancbaum, Jason T Machan, Douglas A Charney, Donald P Kotler.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) has been consistently associated with obesity and insulin resistance. Nonalcoholic steatohepatitis (NASH) is a histological entity within NAFLD that can progress to cirrhosis. The exact prevalence of NASH in severe obesity is unknown. It is unclear whether differences in insulin sensitivity exist among subjects with NASH and simple fatty liver.
OBJECTIVE: To evaluate the prevalence and correlates of NASH and liver fibrosis in a racially diverse cohort of severely obese subjects.
DESIGN: Ninety-seven subjects were enrolled. Liver biopsies, indirect markers of insulin resistance, metabolic parameters, and liver function tests were obtained.
RESULTS: Thirty-six percent of subjects had NASH and 25% had fibrosis. No cirrhosis was diagnosed on histology. Markers of hyperglycemia, insulin resistance, and the metabolic syndrome but not body mass index were associated with the presence of NASH and fibrosis. Elevated transaminase levels correlated strongly with NASH and fibrosis but 46% subjects with NASH had normal transaminases. Subjects with NASH had more severe insulin resistance when compared to those with simple fatty liver. A signal detection model incorporating AST and the presence of diabetes predicted the presence of NASH while another incorporating ALT and HbA1C predicted the presence of fibrosis.
CONCLUSIONS: NAFLD is associated with the metabolic syndrome rather than excess adipose tissue in severe obesity. Insulin resistance is higher in subjects with NASH versus those with simple fatty liver. Statistical models incorporating markers of liver injury and hyperglycemia may be useful in predicting the presence of liver pathology in this population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17311652     DOI: 10.1111/j.1572-0241.2006.01041.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  104 in total

1.  Curcumin diminishes the impacts of hyperglycemia on the activation of hepatic stellate cells by suppressing membrane translocation and gene expression of glucose transporter-2.

Authors:  Jianguo Lin; Anping Chen
Journal:  Mol Cell Endocrinol       Date:  2010-12-30       Impact factor: 4.102

2.  Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  Hüseyin Saadettin Uslusoy; Selim Giray Nak; Macit Gülten
Journal:  World J Hepatol       Date:  2011-08-27

3.  Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease.

Authors:  Brent A Neuschwander-Tetri; Jeanne M Clark; Nathan M Bass; Mark L Van Natta; Aynur Unalp-Arida; James Tonascia; Claudia O Zein; Elizabeth M Brunt; David E Kleiner; Arthur J McCullough; Arun J Sanyal; Anna Mae Diehl; Joel E Lavine; Naga Chalasani; Kris V Kowdley
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

Review 4.  Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future.

Authors:  Emer Fitzpatrick; Anil Dhawan
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

5.  Prevalence of nonalcoholic steatohepatitis in Japanese patients with morbid obesity undergoing bariatric surgery.

Authors:  Yosuke Seki; Satoru Kakizaki; Norio Horiguchi; Hiroaki Hashizume; Hiroki Tojima; Yuichi Yamazaki; Ken Sato; Motoyasu Kusano; Masanobu Yamada; Kazunori Kasama
Journal:  J Gastroenterol       Date:  2015-08-28       Impact factor: 7.527

6.  Current status of therapy in nonalcoholic Fatty liver disease.

Authors:  Scott McNear; Stephen A Harrison
Journal:  Therap Adv Gastroenterol       Date:  2009-01       Impact factor: 4.409

7.  Biochemical determination of lipid content in hepatic steatosis by the Soxtec method.

Authors:  Elizabeth Hijona; Lander Hijona; Mikel Larzabal; Cristina Sarasqueta; Pablo Aldazabal; Juan Arenas; Luis Bujanda
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

8.  A noninvasive clinical scoring model predicts risk of nonalcoholic steatohepatitis in morbidly obese patients.

Authors:  Alex Ulitsky; Ashwin N Ananthakrishnan; Richard Komorowski; James Wallace; Sri Naveen Surapaneni; Jose Franco; Kia Saeian; Samer Gawrieh
Journal:  Obes Surg       Date:  2010-06       Impact factor: 4.129

Review 9.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

10.  Prevalence of nonalcoholic fatty liver disease (NAFLD) and utility of FIBROspect II to detect liver fibrosis in morbidly obese Hispano-American patients undergoing gastric bypass.

Authors:  Gustavo Eugenio Guajardo-Salinas; Ashraf Hilmy
Journal:  Obes Surg       Date:  2009-12-03       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.